Catalyst closes patient enrolment in Phase III LEMS trial
US-based Catalyst Pharmaceutical Partners has completed patient enrolment in a Phase III trial assessing the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Myasthenia Gravis | Pharmaceuticals